Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

Essential oils like rosemary, thyme, lavender, and cedar wood in a carrier oil may effectively treat alopecia areata and potentially male pattern baldness by stimulating the scalp similarly to minoxidil. The user plans to try this routine and share results.

Botox injections increase hair density in patients with androgenetic alopecia. Combining Botox with finasteride yields even better results.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

Low-dose daily aspirin reduces the effectiveness of topical minoxidil in treating androgenetic alopecia. Aspirin inhibits sulfotransferase enzymes, which are necessary for minoxidil to work.

The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Pumpkin seed oil may help hair growth in men with androgenetic alopecia. Treatments discussed include Minoxidil, finasteride, and RU58841.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

A user is considering using melatonin for hair recovery on the side and neck area but is unsure about the best options in Europe and whether a dietary supplement form can be applied to the scalp. They found a product but are hesitant and seeking opinions on its use for alopecia.

The conversation discusses how Tretinoin may improve the effectiveness of Minoxidil for treating hair loss by increasing the activity of certain enzymes in hair follicles. One user comments that this information is not new.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

Comparing the effectiveness of minoxidil 5% and adenosine 0.75% for treating male androgenetic alopecia, and measuring patient satisfaction rate; results showed that adenosine is comparable to minoxidil but provides quicker results, however availability of products with adenosine is much less than those with minoxidil.

Significant hair improvement was reported after 18 months of using 1mg dutasteride and 2.5-5mg oral minoxidil daily for diffuse unpatterned alopecia. The discussion includes praise, skepticism about authenticity, and concerns about side effects.

A user shared a 10-month update on treating hair loss with 1 mg Dutasteride and 2.5-5 mg oral Minoxidil daily, showing significant improvement. Some responses praise the results, others discuss dosing and side effects, and a few comments address the user's previous hostile interactions.

The user has been using dutasteride, lymecycline, betamethasone, and minoxidil for hair loss but struggles with eczema and dry skin. They feel hopeless as no treatments or moisturizers have helped, and they are concerned about their appearance due to their soft facial features.

The conversation is about a person's positive experience with Dutasteride 1mg and Oral Minoxidil 2.5-5mg daily for Diffuse Unpatterned Alopecia, showing significant hair regrowth after 9 months. They mention a tough initial shedding phase, no side effects after 9 months, and a preference for oral treatments due to convenience and pet safety.

A user shared their 7-month progress using 1mg daily Dutasteride and 2.5-5mg daily oral Minoxidil for diffuse unpatterned alopecia, showing significant hair regrowth with reduced shedding and no side effects. They experienced a severe initial shed but now have visual improvement, despite hair still being thinner than before.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

Iron or vitamin deficiencies can lead to decreased hair diameter, not just androgenetic alopecia. Treatments discussed include Minoxidil, finasteride, and RU58841.

Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Topical formulations, natural products, and CAM therapies are being used to treat Androgenic alopecia to avoid side effects of Finasteride and Minoxidil. The review covers various low-risk, alternative treatment options.

The user is seeking advice on the best treatment for male pattern baldness, diffuse thinning, and retrograde alopecia, comparing the effectiveness of finasteride, RU58841, and dutasteride, and considering whether to add minoxidil or switch to dutasteride or combine treatments. They are currently on finasteride and are contemplating if adding RU58841 or switching to dutasteride is better, and also asking about the comparison between pyrilutamide and RU58841.

Treating alopecia androgenetica with limited options, such as spironolacton, dutasteride, finasteride, minoxidil 5%, Rogaine foam for men, a shampoo with ketoconazol, iron supplement and dermarolling.

The user is experiencing hair thinning on the sides and back of the head while the top remains thick. A reply suggests it might be retrograde alopecia.